Zoledronic Acid before and after Surgery in Treating Patients with Grade I-III Chondrosarcoma

Inclusion Criteria

• Male or female patients aged >= 18 years old
• Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
• Written informed consent obtained from subject or the subject’s legally authorized representative prior to participation in the study and any related procedures being performed
• Neutrophil count of > 1500/mm^3
• Platelet count of > 100,000/mm^3
• Hemoglobin >= 9 g/dL
• Aspartate aminotransferase(AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =< 2.5 x upper limit of normal (ULN) or =< 5.0 x ULN if the transaminase elevation is due to disease involvement
• Serum bilirubin =< 1.5 x ULN; for subjects with Gilbert's syndrome, direct bilirubin =< 1.5 x ULN and indirect bilirubin =< 3 x ULN
• Serum creatinine =< 1.5 x ULN or estimated creatinine clearance >= 50 ml/min by Cockcroft-Gault equation
• Total serum calcium (corrected for serum albumin) >= 8.5 mg/dL or ionized calcium >= 3.8 mg/dL
• Serum potassium >= lower limit of normal (LLN)
• Serum sodium >= LLN
• Serum albumin >= 3 g/dl
• Any patient with a biopsy proven diagnosis of chondrosarcoma that is grade I, II or III or in cases where histological and radiological correlation suggests low grade chondrosarcoma as per multidisciplinary discussion
• Patients with biopsy proven dedifferentiated chondrosarcoma that chose not to pursue neoadjuvant chemotherapy are allowed
• Patients must not have received zoledronic acid (ZA) for any reason prior to the study
• Patients with metastatic disease are allowed, if indication to remove primary tumor

Exclusion Criteria

• Prior use of osteoclast inhibitors for osteoporosis within 6 months from screening will not be allowed
• Impaired cardiac function
• Uncontrolled hypertension
• Creatinine > 1.5 or history of renal disease preventing use of ZA
• Other concurrent severe and/or uncontrolled medical conditions including need for urgent dentoalveolar surgery as indicated by preventative dental exam
• Concomitant use of any anti-cancer therapy or radiation therapy
• Women who are pregnant or breast feeding or women of child bearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment; one of these methods of contraception must be a barrier method; WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months)